Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol

SAN FRANCISCO, Jan. 14, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) issued a statement today following a meeting of the Food and Drug Administration ' s (FDA ' s) Anesthetic and Analgesic Drug Products...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news